DelveInsight Business Research LLP

DelveInsight’s, “Lewy Body Disease – Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Lewy Body Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Lewy Body Dementia Market Report Key Highlights 

• Key Companies working for Lewy Body Dementia are as follows Generian Pharmaceuticals, Aptinyx, Eli Lilly and Company, Sun Pharma, CuraSen Therapeutics, NeuroActiva, Neurimmune Therapeutics, Voyager Therapeutics, and many others 
• Key Therapies included for Lewy Body Dementia are as follows Irsenontrine, Neflamapimod, Mevidalen and many others 

Got queries? Click here to learn more about the Lewy Body Dementia Pipeline 

Lewy Body Dementia Overview

Lewy Body Disease is caused by the degeneration and death of nerve cells in the brain. The name comes from the presence of abnormal spherical structures, called Lewy bodies, which develop inside nerve cells. It is thought that these may contribute to the death of the brain cells. They are named after the doctor who first wrote about them. It is sometimes referred to as Diffuse Lewy Body Disease. At present there is no known cause of Lewy Body Disease, and no known risk factors have been identified. There is no evidence that it is an inherited disease. This type of dementia is diagnosed by taking a careful history of the pattern of symptoms, and by excluding other possible causes such as Vascular dementia and Alzheimer’s disease. A brain scan may reveal brain degeneration, but the Lewy bodies can only be identified by examination of brain tissue after death. At present there is no cure for Lewy Body Disease. Symptoms such as depression and disturbing hallucinations can usually be reduced by medication. However, medications to relieve hallucinations may increase muscle tremors and stiffness. Conversely, anti-Parkinson drugs may make hallucinations worse.

Lewy Body Dementia Epidemiological Insights 

• According to DelveInsight estimates, the US accounted for approximately 305 thousand cases, the highest diagnosed Lewy Body Dementia prevalent cases, followed by Japan with around 213 thousand cases, and EU4 and the UK with 202 thousand cases in 2022. These cases are expected to increase in the US, EU4 and the UK, and Japan by 2032
• Among the EU4 and the UK, the UK had the highest Lewy Body Dementia diagnosed prevalent population (approximately 47 thousand cases), followed by Germany (approximately 45 thousand cases) in 2022. On the other hand, Spain (30 thousand cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.

Lewy Body Dementia Epidemiological Segmentation 

• Lewy Body Dementia prevalent population
•  Lewy Body Dementia gender-specific prevalent population  
•  Lewy Body Dementia diagnosed cases 
•  Lewy Body Dementia treatable cases 

Learn more by requesting the sample of the report @ Lewy Body Dementia

Lewy Body Dementia Key Companies

• Generian Pharmaceuticals, 
• Aptinyx, 
• Eli Lilly and Company, 
• Sun Pharma, 
• CuraSen Therapeutics, 
• NeuroActiva, 
• Neurimmune Therapeutics, 
• Voyager Therapeutics,

And many others 

 Lewy Body Dementia Therapies

• Irsenontrine
• Neflamapimod
• Mevidalen 

And many others 

Table of Contents

• Key Insights 
•  Report Introduction
• Executive Summary of Lewy Body Dementia
• Disease Background and Overview
•  Epidemiology and patient population
•  Lewy Body Dementia  Emerging Therapies
•  Lewy Body Dementia Market Outlook
• Market Access and Reimbursement of Therapies
•  Appendix
•  Lewy Body  Report Methodology
•  DelveInsight Capabilities
• . Disclaimer
•   About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services